Search
Patexia Research
Case number 1:22-cv-00696

Aragon Pharmaceuticals, Inc. et al v. Hetero Labs Limited Unit V et al > Documents

Date Field Doc. No.Description (Pages)
Aug 1, 2022 N/A SO ORDERED (0)
Docket Text: SO ORDERED, re [12] Stipulation Extending Deadline to Respond to Complaint, filed by Hetero USA, Inc., Hetero Labs Limited Unit V. Reset Answer Deadlines: Hetero Labs Limited Unit V answer due 8/16/2022; Hetero USA, Inc. answer due 8/16/2022. Ordered by Judge Colm F. Connolly on 8/1/2022. (kmd)
Aug 1, 2022 12 Stipulation (3)
Docket Text: STIPULATION and [Proposed] Order Extending Deadline to Respond to Complaint re [1] Complaint, by Hetero Labs Limited Unit V, Hetero USA, Inc.. (Ferraro, April)
Jul 5, 2022 10 Notice of Appearance (1)
Docket Text: NOTICE of Appearance by John M. Seaman on behalf of Hetero Labs Limited Unit V, Hetero USA, Inc. (Seaman, John)
Jul 5, 2022 11 Notice of Appearance (1)
Docket Text: NOTICE of Appearance by April M Ferraro on behalf of Hetero Labs Limited Unit V, Hetero USA, Inc. (Ferraro, April)
Jun 3, 2022 8 Waiver of Service Executed (1)
Docket Text: WAIVER OF SERVICE returned executed by Janssen Biotech, Inc., Aragon Pharmaceuticals, Inc., The Regents of the University of California, Sloan-Kettering Institute for Cancer Research: For Hetero Labs Limited Unit V waiver sent on 6/3/2022, answer due 8/2/2022. (Blumenfeld, Jack)
Jun 3, 2022 9 Waiver of Service Executed (1)
Docket Text: WAIVER OF SERVICE returned executed by Janssen Biotech, Inc., Aragon Pharmaceuticals, Inc., The Regents of the University of California, Sloan-Kettering Institute for Cancer Research: For Hetero USA, Inc. waiver sent on 6/3/2022, answer due 8/2/2022. (Blumenfeld, Jack)
Jun 1, 2022 N/A Case Assigned/Reassigned (0)
Docket Text: Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:22-cv-00678-CFC, 1:22-cv-00688-CFC, 1:22-cv-00696-CFC (rjb)
May 27, 2022 1 Main Document (29)
Docket Text: COMPLAINT filed against Hetero Labs Limited Unit V, Hetero USA, Inc. ( Filing fee $ 402, receipt number ADEDC-3883677.) - filed by Janssen Biotech, Inc., Aragon Pharmaceuticals, Inc., The Regents of the University of California, Sloan-Kettering Institute for Cancer Research. (Attachments: # (1) Exhibit A-F, # (2) Civil Cover Sheet)(twk)
May 27, 2022 1 Exhibit A-F (182)
May 27, 2022 1 Civil Cover Sheet (2)
May 27, 2022 2 Magistrate Consent Forms (3)
Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk)
May 27, 2022 3 ANDA Form (1)
Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 4/19/2022. Date of Expiration of Patent: U.S. Patent No. 8,445,507 expires on September 15, 2030; U.S. Patent No. 9,481,663 expires on June 4, 2033; and U.S. Patent Nos. 9,884,054; 10,052,314 and 10,849,888 expire on September 23, 2033. U.S. Patent No. 10,702,508 expires on April 30, 2038. Thirty Month Stay Deadline: 8/14/2025. (twk)
May 27, 2022 4 Patent/Trademark Report to Commissioner (1)
Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,445,507 B2; 9,481,663 B2; 9,884,054 B2; 10,052,314 B2; 10,702,508 B2; 10,849,888 B2. (twk)
May 27, 2022 5 Disclosure Statement (2)
Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc. No Parents or Affiliates Listed for The Regents of the University of California, Sloan-Kettering Institute for Cancer Research - filed by Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan-Kettering Institute for Cancer Research, The Regents of the University of California.
May 27, 2022 6 Summons Issued (2)
Docket Text: Summons Issued as to Hetero Labs Limited Unit V on 5/27/2022. (twk)
May 27, 2022 7 Summons Issued (2)
Docket Text: Summons Issued as to Hetero USA, Inc. on 5/27/2022. (twk)
May 27, 2022 1 Complaint* (1)
Menu